Concordance between plasma cfDNA and tumor gDNA genotyping in 16 patients with paired tumor/plasma patients in the training cohort. (A) The percentage of tumor biopsy–confirmed mutations that were detected in cfDNA. (B) The number of mutations discovered in baseline plasma cfDNA and/or tumor gDNA. (C) Comparison of AFs of mutations identified in baseline tumor gDNA and plasma cfDNA. (D) Scatter plot of mutation AF in cfDNA vs AF in tumor gDNA for each variant.